Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc.Sep 13 2010

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7^th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4^th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, whose agenda can be found at:

(http://www.melanoma2010.com/pdf/Melanoma_Centres_program.pdf)

Efficacy data on the full study population will be presented, including response rate and time-to-event (progression-free- survival and overall survival). Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, and Principal Investigator for Provectus's Phase 2 PV-10 trial site at St. Luke's, will be delivering the presentation.

Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, "The final follow-up on all 80 subjects enrolled in the Phase 2 study was completed in May 2010. We are extremely excited about the efficacy, progression-free-survival and overall survival data to be presented, which we believe will be comparable to the interim data presented at the ASCO meeting in June. These data confirm our belief that PV-10 compares favorably with available and emerging options for this patient population, making it an attractive candidate for commercial development, and we look forward to Dr. Agarwala's presentation."